MSIF has formed a mutually beneficial relationship with the corporate sector over many years. The development of MS treatments and other products has led to growing interest in the work of the MS International Federation by healthcare companies. As a result they have supported MSIF projects that have benefited people with MS around the world.

Although much attention has been focused on the pharmaceutical and biotech industries, there are other health sectors that may wish to support MSIF and its member MS societies. These include manufacturers and suppliers of medical devices and aids to daily living, dietary supplements, health management organisations, nursing/homecare agencies and insurers.

Healthcare companies are important stakeholders in the MS space and where we have shared goals we welcome their support of our work. We also recognise that not all of our goals are aligned so do not accept any interference or influence over any programme design or delivery. In support of this we also always try to secure multi-stakeholder funding for projects to reduce the risk of individual influence.

To acknowledge the unique role of healthcare companies in the MS space we have a detailed policy covering our engagement with them. This covers relationships involving financial arrangements, and non-financial relationships.

For an overview of support from the healthcare industry in 2019 please visit our ‘income to date‘ page.

2018 healthcare industry support

The information below shows the exact amount we received from the healthcare industry in 2018 and the programmes they supported.


Sanofi Genzyme – Total: £167,612

  • Access to effective treatment £20,000
  • Informed decision making (Communicating about MS): £50,000
  • Atlas of MS: £5,000
  • Arabic speaking region capacity building: £40,000
  • Latin America capacity building: £20,000
  • Asia capacity building £25,000
  • Global capacity building (including MS World Conference 2018) £7,612

Merck – Total: £152,607

  • Research awards £17,607
  • Access to effective treatment £20,000
  • Informed decision making: £40,000
  • World MS Day: £20,000
  • Atlas of MS: £5,000
  • Arabic speaking region capacity building: £10,000
  • Latin America capacity building: £15,000
  • Global capacity building (including MS World Conference 2018): £10,000
  • Kiss Goodbye to MS £15,000

Biogen – Total: £37,410

  • World MS Day: £17,410
  • Arabic speaking region capacity building: £20,000

Roche – Total: £115,000

  • Access to effective treatment £20,000
  • Informed decision making (Communicating about MS): £35,000
  • World MS Day: £20,000
  • Atlas of MS: £5,000
  • Arabic speaking region capacity building: £10,000
  • Latin America capacity building: £10,000
  • Global capacity building: £5,000
  • Kiss Goodbye to MS £10,000

Celgene – Total: £51,609

  • Access to effective treatment £11,737
  • Informed decision making (Communicating about MS): £11,598
  • World MS Day: £11,312
  • Atlas of MS: £5,654
  • Global capacity building: £5,654
  • Kiss Goodbye to MS £5,654

Novartis – Total: £42,040

  • World MS Day: £20,000
  • Global capacity building (including MS World Conference 2018): £22,040

Page Tags: